Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme (DSP) dataset evaluating how HAE is managed in clinical practice have been published in Advances in Therapy.

The analysis evaluated real-world patterns of HAE disease management including frequency, severity, and characteristics of HAE attacks; use of long-term prophylaxis (LTP) and on-demand treatment (ODT); patient and physician decision-making around treating or not treating attacks; treatment adherence and reasons for suboptimal adherence; and patient and physician perspectives on treatment satisfaction and unmet needs.

“By incorporating both physician-reported clinical data and patient-reported experiences, this analysis provides a comprehensive view of how hereditary angioedema is managed in routine clinical practice,” said Peng Lu, M.D., Ph.D., President of Pharvaris. “Early diagnosis and effective treatment remain critical, yet this real-world analysis highlights remaining gaps between guideline-recommended care and the actual experience of people with HAE. Addressing these gaps may help improve treatment outcomes, enhance patient satisfaction, and optimize overall disease management. These findings highlight the importance of understanding how treatment decisions are made in real-world settings and the barriers that may still limit alignment with clinical guidelines. At Pharvaris, we are committed to supporting the HAE community by leveraging insights to inform decisions and to identify solutions that may further inform medical care and address the practical and clinical needs of patients and physicians in everyday practice.”

Study Insights
The analysis identified gaps that currently persist between guideline-recommended care and real-world practice. Patient satisfaction with treatment and the decision to change treatment were mostly driven by ease of portability, route of administration, perceived efficacy, and the odds of experiencing adverse events. In addition, treatment burden—particularly related to route of administration, convenience, and integration into daily life—continues to impact patient behavior and satisfaction.

With regards to on-demand treatment of attacks, a substantial proportion of patients do not treat all HAE attacks, most commonly because attacks are perceived as not severe enough to use treatments patients perceive being associated with increased burden. Other reasons included the lack of availability of therapy and pain associated with injectable treatments. With regards to LTP treatment satisfaction, daily oral treatment was preferred over biweekly or monthly injections. These findings highlight ongoing unmet needs and suggest that real-world factors, including patient preferences and treatment usability, play a critical role in treatment outcomes.

Study Details
The analysis used data from the Adelphi Real World HAE DSP, a cross-sectional, retrospective survey conducted between January 2023 and January 2024 across the United States, Europe, and Japan. The study included 225 physicians, who completed record-based assessments for 1,131 patients with HAE, as well as 279 patients who provided direct, self-reported insights through questionnaires. This dual approach enabled comparison of physician-reported clinical data with patient-reported experiences, offering a comprehensive view of real-world HAE management. The survey captured both clinical characteristics and patient perspectives, including treatment behaviors and quality-of-life impact. Although the HAE treatment landscape has evolved between the time of the survey and present, the findings from the study are still considered actual.